Clinical
Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study
This retrospective study evaluated the efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients (≥65 years) with advanced lung adenocarcinoma lacking driver gene alterations. Among 169 included patients, the bevacizumab-treated group demonstrated a median overall survival of 47 months and a median progression-free survival of 24 months. Multivariate analysis identified bevacizumab as an independent favorable prognostic factor for both progression-free and overall survival. Biomarkers related to inflammation, nutrition, and tumor burden were also associated with prognosis.